aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
29. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
27. September 2022 08:00 ET
|
aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
13. September 2022 08:00 ET
|
aTyr Pharma, Inc.
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...
aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
06. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
01. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
15. August 2022 16:00 ET
|
aTyr Pharma, Inc.
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12. August 2022 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
11. August 2022 08:03 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
04. August 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
14. Juni 2022 08:00 ET
|
aTyr Pharma, Inc.
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have...